XML 38 R24.htm IDEA: XBRL DOCUMENT

SUBSEQUENT EVENT	6 Months Ended
SUBSEQUENT EVENT	Jun. 30, 2019
Subsequent Events [Abstract]
Subsequent Event	SUBSEQUENT EVENT In August 2019, following a strategic review of the CNSA-001 program in patients with phenylketonuria (PKU), the Company made the decision to decline to exercise its option to acquire Censa Pharmaceuticals and accordingly discontinue its joint development program for CNSA-001. The Company expects to impair the $15 million long term investment on the balance sheet during the third quarter of 2019.